Member Info for Ivyspivey

If approved for the ABSSSI indication as a New Chemical Entity, iclaprim will be eligible for 10 years of market exclusivity in the U.S., with a similar deal anticipated to take place in Europe.

The company is also building a patent estate for its iclaprim product, including its use to treat patients with bacterial infections, hospital-acquired bacterial pneumonia, and Staphylococcus aureus lung infections in cystic fibrosis patients.

The company’s experienced board has a strong track record in financing and operating pharmaceutical and biotech products, and have been delivering on its stated objectives since IPO. Listed on both AIM and NASDAQ, its institutional shareholding includes Invesco Ltd ($980.9 billion AUM), M&G Investments (£351bn AUM), Sand Grove Capital ($1.202 billion AUM) and Amphion Innovations (AMP).

Shares in MTFB are currently trading at 30p each

Motif Bio is set to garner further interest with its attendance at the Jeffries London Healthcare Conference, the largest healthcare-dedicated conference in Europe on the 14th-15th November. In 2017, the event hosted over 400 companies, 1,800 attendees and 4,500 business-to-business and investor meetings.

Participants include leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from around the world.

Graham Lumsden, CEO of Motif Bio, commented: “This is a prestigious event attended by leading healthcare executives and is a great opportunity to meet different classes of investor and other companies in the healthcare space.”

It brings together leading healthcare executives, institutional, private equity and venture capital investors to allow them to identify near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.

He added: “We will also be participating in one-on-one meetings throughout the two days and look forward to sharing the developing Motif story.”

With a £86m market cap and a unique market cap, opportunistic analysts and investors will be watching companies like Motif Bio closely.

Motif Bio (MTFB)
Follow
are on a mission to provide doctors with more options to combat drug resistant “superbugs”.

The company is a clinical-stage biopharmaceutical firm focused on developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA (known as “superbugs”).

It has had successful Phase 3 trials for its lead product candidate Iclaprim, recently submitting a New Drug Application to the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), now under priority review, with a PDUFA date set for 13 February 2019.

G. Ralph Corey, MD, Professor at Duke University School of Medicine said: “Iclaprim could be a valuable treatment option for patients with wound infections suspected or confirmed to be due to Gram-positive pathogens, including patients with co-morbidities known to increase the risk of vancomycin-associated acute kidney injury, such as renal impairment, diabetes and obesity."

With more than 3.6 million patients with ABSSSI hospitalised annually in the U.S, and of those up to 26% of patients suffering from kidney function (renal) impairment, Motif Bio could be set to attain a significant market share among these patients.

**************************************/articles/why-you-need-to-follow-motif-bio-s-fight-against-superbugs-c00f81f/

M&G Group<br />15,177,151<br />Or 5.1% of shares is latest info on MTFB website and is dated September 2018 so if the latest share register is showing 19.1m shares or 6.6% it is new news but surprised a TR1 has not been seen unless it comes on Monday.

151

Yes a good week and agree look like buys to me

The LTH are fully aware of this pattern.
Lots of ATs just before Nasdaq opening to try and spook people into selling.Thecappearancevif certain posters just confirms they are working in harness.
What bad news are we expecting.
Iclaprim is being considered by FDA and PDUFA date is 13th Feb.
Highlighting Director Buys shows a total misunderstanding of how US pharma worksvwhivh MTFB follow.
The BOD and the institutional SH here are totally aligned with LTH.
If GL did buy Petch would be the first on here saying Panic buy to support the SP so until there is bad news of which I can’t think of sny I will not sell any.
Last time we had this kind of behaviour was pre R1 and R2 results and NDA acceptance of all which very positive so imo be patient.
Also look at the high UT last night so that any drop can be highlighted.
Sio done is wanting to test the lows. But tot must be worth fighting for.
Very confident here and who do you believe a new poster with 67 il informed negative posts or the LTH who have never been afraid to discuss all points positive and negative.
ATB

Morning Botski
Presumably that was hinted at during presentation or did you get info in private chat afterwards.
Wonder if they have reducedvGC number of winners if prize will be higher

Thanks for contribution.
I know GL has talked to a few CSOs over the last 18 months and if they found it hard to do a partner deal and could find a CSOnpartner with the necessay contacts and the know how to readily explain the economic model critical to commercialising Iclaprim.They will certainly not go down the road of a detail slot.
All the corporate presentations state the preferred option is a partner in the hospital space.I know GL well enough to know if they had changed the strategy and wanted to go down CRO line/commercialising themselves there would have been hints in presentations etc.There has been none.

Just listened and seems very positive.
Any recent investors should definitely watch

No worries.Also clearly mentions if they were to go it alone they would have to recruit MSLs 6 months before PDUFA date which is 13th Feb.
So 3.5 months away and no one recruited yet as far as I am aware.

If you think that MTFB will go it alone on US Commercialisation please re listen to this I/v

https://www.youtube.com/watch?v=RINfaFGnOnc

Yes Douve
They have compelling data on SCIB 1 mono therapy but the Combo data will interest many big players especially those with CIs if it is validated.
As for Modi imo you need clinical data ie human t9 get any real value inflection point.Plus there are many other irons in fire which have been validated and taken on by third parties which should not be underestimated.

Post recommended and a very good analogy.
You asked the question sompleased you were happy with answer.
It was early days for CH and do think he has taken on mantle pretty well.
We all know the science is what will determine things here with a few infection points possibly before that like GC/TCR and SCIB2 but for cancer sufferers and the SP it is SCIB 1 Combo and Mod Clinical results where the LTH will sink or swim.
Had good chat with Alan Lewis afterwards and sure all the remuneration comments and KCB departure are not related and all very amicable

Agree WW
Lindy presentation imperious and very impressed with role Sally Adams is getting so make a grearpt technical team plus all the great work done by others in the background

Again they are a US Company.
Sales in UK are at least 15 months away so plenty of time to build story here.
It is all about the partnership deal I said if MTFB were going to commercialise itself then this type ofvPRcmay bevuseful but far more important to progress things via big players and this is done by personal contact

Hi Aubree
Of course Ringworm is a very nasty fungal infection rather than a nematidebir cestode( roundworm/ltapewirm)

Not sure if this point as been made here but some discussion on other board.
The Kickmuck comment about the 15m sellers being a transfer of some kind from old service providers to some new entity has extra credence given the Baker Hughes tie up

The potential and target market for Iclaprim is not as an alternative drug to be used in AMR cases.
This issue is only as background to the impending crisis which it taps into very well.
They do not want Iclaorim to be closely associated with the AMR debate for strategic reasons.
To repeat and please try and understand it is target vs MRSA and MSSA in renally impaired patients with a very low propensity for resistance.

Think Timbo is going tonight and look forward to his feedback.
Met him at 2017 AGM and is imo a genuine and unbiased investor who knows his stuff.Particularly interested in his comments re delivery devices as know he has big issue with Trigid 1.
C7- no worries and any apologies accepted and hope you are feeling better soon.At times if I am having a seemingly heated discussion with Inan I think it is unfair on the rest of the board but we just take a different view on many things and probably are both determined to stick to our guns and are both big and ugly enough to not get upset by our disagreements.
My father actually died of COPD but not surprising as was a miner for 48 years and lived to a very decent age so no real complaints.
ATB everyone